Booster do work
June 13, 2026
28 min
Full
115 of 364
June 13, 2026
Booster do work
0:00 / 28:06
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Dr John Campbell Episodes Around June 13, 2026
Episode 115 of 364 — walk the feed in the order it was published.
28:06This episodeBooster do work
Summary
Booster doses probably needed by most people, unfortunately.
https://ourworldindata.org/covid-vaccinations
https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination
US, 20.6 million so far
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
Six months after 2nd shot
65 years and older
50–64 years with underlying medical conditions
18 – 64 years, working / living in high-risk settings
18 years and older, 2 months Johnson & Johnson/Janssen
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel (NEJM, October 2021)
https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1
https://www.nejm.org/doi/full/10.1056/NEJMoa2114255?
July 30, 2021, over 602
Third (booster) dose of the Pfizer BNT162b2 vaccine was approved
60 years or older who had been fully vaccinated
August 29th, anyone over 12
At least five months previously
N = 1,144,690
2 dynamic cohorts
2 vaccines only
N = 5.2 million person days
4,439 confirmed infections
294 cases of severe covid
(based on 4.6 million person days)
2 vaccines + booster
N = 10.6 million person days
934 confirmed infections
29 cases of severe COVID-19
(based on 6.3 million person days)
(despite older demographic)
Twelve days or more after the booster dose
Increases antibody neutralization levels ~10-fold compared to after 2nd dose
11.3 fold decrease in the relative risk of confirmed infection
Efficacy among booster recipients to approximately 95%
(May have waned to 50% with time and delta variant)
https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1
19.5 fold decrease in the relative risk of severe illness
Factor reduction in reduced rate of confirmed infection in boosted versus none-boosted
In conjunction with safety reports
this study demonstrates the effectiveness of a third vaccine dose,
in both reducing transmission and severe disease,
indicates the great potential of curtailing the Delta variant resurgence by administering booster shots
Decline in immunity, UK data
https://www.gov.uk/government/news/over-eight-million-people-in-the-uk-receive-covid-19-booster-jabs
Protection against symptomatic disease, Oxford/AstraZeneca vaccine